Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Key Findings:  Although the studies are scarce, CBD seems to be effective on treating dystonic movements, both primary and secondary. It is noteworthy that in some cases, particularly concerning multiple sclerosis and HD, the clinical beneficial effects are observed only when CBD is combined with Δ9-THC in a 1:1 ratio (Sativex). In fact, these therapeutic effects are probably due to Δ9-THC, since they are also seen with other cannabinoid agonists . Nonetheless, CBD is shown to diminish the Δ9-THC unwanted effects, such as sedation, memory impairments, and psychosis. Data suggest that CBD's might have a preventive role rather than a therapeutic one in PD. The molecular mechanisms associated with CBD's improvement of motor disorders are likely multifaceted. Data show that it might depend on CBD's actions on 5-HT1A, CB1, CB2, and/or PPARγ receptors.

Type of Study:  Meta-analysis

Study Result:  Positive

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified), Pharma THC:CBD

Phytocannabinoid Source:  Not Applicable

Chemotype:  Chemotype II, Chemotype I, Chemotype III

Form of Administration:  Inhalation, Ingestion, Sublingual

Receptors Studied:  CB1, CB2, PPAR - Gamma

Ligands Studied:  Serotonin

Study Location(s):  Brazil

Year of Pub:  2018

Link to study